{"id":5815,"date":"2023-09-04T03:39:59","date_gmt":"2023-09-04T03:39:59","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-analysis-result\/calgb50303-tumor-annotations\/"},"modified":"2023-11-22T00:25:29","modified_gmt":"2023-11-22T00:25:29","slug":"calgb50303-tumor-annotations","status":"publish","type":"tcia_analysis_result","link":"https:\/\/cm.vastapps.dev\/tcia-analysis-result\/calgb50303-tumor-annotations\/","title":{"rendered":"CALGB50303-TUMOR-ANNOTATIONS"},"featured_media":0,"template":"","cancer_types":["Lymphoma"],"citations":[4844,2925],"full_export":"

Summary<\/h1>\r\nThis dataset contains image annotations derived from the NCI Clinical Trial \"Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma (CALGB50303)<\/a>\u201d. \u00a0This dataset was generated as part of an NCI project to augment TCIA datasets with annotations that will improve their value for cancer researchers and AI developers.<\/span><\/span>\r\n

Annotation Protocol<\/strong><\/h4>\r\nFor each patient, every DICOM Study and DICOM Series was reviewed to identify and annotate the clinically relevant time points and sequences. In a typical patient all available time points were annotated.\r\n\r\nIn a typical patient the following annotation rules were followed:\r\n

a. \u00a0 \u00a0PERCIST criteria was followed. Specifically, the lesions estimated to have the most elevated SUVmax were annotated.\r\nb. \u00a0 \u00a0Lesions were annotated in the axial plane. If no axial plane were available, lesions were annotated in the coronal plane.\r\nc. \u00a0 \u00a0Lesions were annotated on the attenuation corrected PET series as well as the diagnostic contrast-enhanced CT. If no diagnostic contrast-enhanced CT was available for that timepoint, then the non-contrast CT portion of the PET\/CT was annotated.\r\nd. \u00a0 \u00a0A maximum of 5 lesions were annotated per patient scan (timepoint); no more than 2 per organ. For the purposes of this project, the lymph nodes constitute 1 organ, while other lymphatic structures such as the spleen, salivary glands, and Waldeyer\u2019s ring structures constitute separate organs. \u00a0The same 5 lesions were annotated at each time point. \u00a0RECIST 1.1 principles were followed. Specifically, lymph nodes were annotated if > 1.5 cm in short axis. Other lesions were annotated if > 1 cm.\r\ne. \u00a0 \u00a0Lesions were labeled separately.\r\nf. \u00a0 \u00a0Seed points were automatically generated and reviewed by a radiologist.<\/p>\r\nAt each time point:\r\n

    \r\n \t
  1. A seed point (kernel) was created for each segmented structure. The seed points for each segmentation are provided in a separate DICOM RTSS file.<\/li>\r\n \t
  2. SNOMED-CT \u201cAnatomic Region Sequence\u201d and \u201cSegmented Property Category Code Sequence\u201d and codes were inserted for all segmented structures.<\/li>\r\n \t
  3. \u201cTracking ID\u201d and \u201cTracking UID\u201d tags were inserted for each segmented structure to enable longitudinal lesion tracking.<\/li>\r\n \t
  4. Imaging time point codes were inserted to help identify each annotation in the context of the clinical trial assessment protocol.\r\n
      \r\n \t
    1. \u201cClinical Trial Time Point ID\u201d was used to encode time point type using one of the following strings as applicable: \u201cpre-dose\u201d or \u201cpost-chemotherapy\u201d<\/li>\r\n \t
    2. Content Item in \u201cAcquisition Context Sequence\u201d was added containing \"Time Point Type\" using Concept Code Sequence (0040,A168) selected from:\r\n
        \r\n \t
      1. (255235001, SCT, \u201cPre-dose\u201d)<\/li>\r\n \t
      2. (262502001, SCT, \"Post-chemotherapy\")<\/li>\r\n<\/ol>\r\n<\/li>\r\n<\/ol>\r\n<\/li>\r\n<\/ol>\r\n

        Important supplementary information and sample code<\/h3>\r\n
          \r\n \t
        1. A spreadsheet containing key details about the annotations is available in the\u00a0Data Access<\/strong>\u00a0section below.<\/li>\r\n \t
        2. A\u00a0Jupyter notebook demonstrating how to use the\u00a0NBIA Data Retriever Command-Line Interface<\/a>\u00a0application and the\u00a0REST API (with authentication)<\/a>\u00a0to access these data can be found in the\u00a0Additional Resources<\/strong>\u00a0section below.<\/li>\r\n<\/ol>\r\n \r\n
          \r\n
          \r\n
          \r\n